Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Alexandra Gomez-Arteaga, MD, Nina Orfali, MB,PhD, Danielle Guarneri, BS, CCRP, Usama Gergis, MD MBA, Sebastian A. Mayer, MD, Jingmei Hsu, MD, Adrienne A. Phillips, MD MPH, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD

Blood (2019) 134 (Supplement_1): 2040.

https://doi.org/10.1182/blood-2019-129584

Published: 2019

Journal Articles

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Sarah Agamah, MBA, MPH

Blood (2019) 134 (Supplement_1): 3472.

https://doi.org/10.1182/blood-2019-130505

Published: 2019

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood

Blood (2019) 134 (Supplement_1): 4587.

https://doi.org/10.1182/blood-2019-124634

Published: 2019

Journal Articles

Relapse-Initiating Clones Preexisting at Diagnosis in B- Cell Acute Lymphoblastic Leukemia Help Predict Molecular Pathways of Relapse

Blood (2018) 132 (Supplement 1): 915.

https://doi.org/10.1182/blood-2018-99-118998

Published: 2018

Journal Articles

Socioeconomic Status and Outcomes Among Mexican Patients Undergoing Allogeneic Stem Cell Transplantation

Eucario Leon Rodriguez, MD, Monica M Rivera Franco

Blood (2018) 132 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2018-99-110958

Published: 2018

Journal Articles

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Luke Mountjoy, DO, Katie L. Kunze, PhD, Tania Jain, MD, James L. Slack, MD, Nandita Khera, MD, Jose F. Leis, MD PhD, Pierre Noel, MD, Lisa Z. Sproat, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2018-99-112217

Published: 2018

Journal Articles

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Monzr M. Al Malki, MD, Joo Y. Song, MD, Dongyun Yang, PhD, Thai Cao, MD, Ibrahim Aldoss, MD, Sally Mokhtari, PhD, Sanjeet Dadwal, MD, Ketevan Gendzekhadze, PhD, Anna B Pawlowska, MD, Maryam Ameri, MD, Guido Marcucci, MD, Chatchada Karanes, Pablo Parker, MD, David S. Snyder, MD, David Senitzer, PhD, Auayporn P. Nademanee, MDBS, Stephen J. Forman, MD FACP, Ryotaro Nakamura, MD, Vinod Pullarkat, MD MRCP

Blood (2017) 130 (Supplement 1): 3212.

https://doi.org/10.1182/blood.V130.Suppl_1.3212.3212

Published: 2017

Journal Articles

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, CCRP, Katelin C Jackson, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem M Solh, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 4608.

https://doi.org/10.1182/blood.V130.Suppl_1.4608.4608

Published: 2017

Journal Articles

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Jackson, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2016) 128 (22): 661.

https://doi.org/10.1182/blood.V128.22.661.661

Published: 2016

Journal Articles

Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation

Blood (2016) 128 (22): 3492.

https://doi.org/10.1182/blood.V128.22.3492.3492

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)

Michele Pohlen, MD, Christoph Groth, MD, Tim Sauer, MD, Dennis Görlich, Rolf Mesters, MD, Christoph Schliemann, MD, Georg Lenz, MD, Carsten Müller-Tidow, MD, Thomas Büchner, MD, Wolfgang E Berdel, MD, Matthias Stelljes, MD

Blood (2015) 126 (23): 2025.

https://doi.org/10.1182/blood.V126.23.2025.2025

Published: 2015

Journal Articles

Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients

Blood (2015) 126 (23): 4400.

https://doi.org/10.1182/blood.V126.23.4400.4400

Published: 2015

Journal Articles

Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment

Nelli Bejanyan, MD, Claudio G Brunstein, MD, Qing Cao, Aleksandr Lazaryan, MD PhD MPH, Erica D. Warlick, MD, Celalettin Ustun, MD, Shernan G. Holtan, MD, Mukta Arora, MD, Veronika Bachanova, MD, Michael R. Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD

Blood (2015) 126 (23): 4375.

https://doi.org/10.1182/blood.V126.23.4375.4375

Published: 2015

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon

Blood (2014) 124 (21): 680.

https://doi.org/10.1182/blood.V124.21.680.680

Published: 2014

Journal Articles

Use of the Dana-Farber/CIBMTR Disease Risk Index (DRI) to Compare Outcomes of T-Replete HLA-Haploidentical Transplants Using Post-Transplant Cyclophosphamide to Matched Sibling and Matched Unrelated Donor Transplants : A Multivariate Analysis of 498 Contemporaneous Allogeneic Transplants from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 1203.

https://doi.org/10.1182/blood.V124.21.1203.1203

Published: 2014

Journal Articles

Clinical Significance of Risk Stratification Based on Disease Risk Index and Hematopoietic Cell Transplantation-Comorbidity Index

Takayuki Sato, MD PhD, Shinichi Ochi, MD, Takashi Nagayama, MD, Shogo Nabe, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Hiroyuki Sugiura, MD, Kazuya Okada, MD, Aki Sato, MD PhD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Yasunori Ueda, MD PhD

Blood (2014) 124 (21): 2539.

https://doi.org/10.1182/blood.V124.21.2539.2539

Published: 2014

Journal Articles

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Philippe Armand, Haesook T. Kim, Brent R. Logan, Zhiwei Wang, Edwin P. Alyea, Matt E. Kalaycio, Richard T. Maziarz, Joseph H. Antin, Robert J. Soiffer, Daniel J. Weisdorf, J. Douglas Rizzo, Mary M. Horowitz, Wael Saber

Blood (2014) 123 (23): 3664–3671.

https://doi.org/10.1182/blood-2014-01-552984

Published: 2014

Journal Articles

Romano M, Dri P, Dadalt L, Patriarca P, Baralle FE. Biochemical and molecular characterization of hereditary myeloperoxidase deficiency. Blood . 1997;90(10): 4126-4134 .

Blood (2013) 121 (25): 5104.

https://doi.org/10.1182/blood-2013-05-502021

Published: 2013

NARROW

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood

Relapse-Initiating Clones Preexisting at Diagnosis in B- Cell Acute Lymphoblastic Leukemia Help Predict Molecular Pathways of Relapse

Socioeconomic Status and Outcomes Among Mexican Patients Undergoing Allogeneic Stem Cell Transplantation

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation

Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)

Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients

Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Clinical Significance of Risk Stratification Based on Disease Risk Index and Hematopoietic Cell Transplantation-Comorbidity Index

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Romano M, Dri P, Dadalt L, Patriarca P, Baralle FE. Biochemical and molecular characterization of hereditary myeloperoxidase deficiency. Blood . 1997;90(10): 4126-4134 .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only